Daily Archives: April 9, 2021
RCT: Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
9 Apr, 2021 | 03:18h | UTCAuthor Interview: Effect of High-Frequency (10 kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
Commentary on Twitter
Thrilled to see our publication out today in @JAMANeuro using #SCS to treat #diabetic #pain. 86% of patients with over 50% pain relief at 6 months with better sleep and walking! #progress #needherscience #neuromodulation @UAMSneurosurg @UAMSPain @uamshealth https://t.co/TJQPHsHvSa
— Dr. Erika Petersen (@ErikaPetersenMD) April 5, 2021
Viewpoint | Reducing Low-Value Care and Improving Health Care Value
9 Apr, 2021 | 03:23h | UTCReducing Low-Value Care and Improving Health Care Value – JAMA (free for a limited period)
Guidelines of care for the management of actinic keratosis
9 Apr, 2021 | 03:20h | UTC
Short Review | How to use antihistamines
9 Apr, 2021 | 03:13h | UTCHow to use antihistamines – Canadian Medical Association Journal
AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude
9 Apr, 2021 | 03:33h | UTC
A guide to Plan S: the open-access initiative shaking up science publishing
9 Apr, 2021 | 03:11h | UTCA guide to Plan S: the open-access initiative shaking up science publishing – Nature
Related: Open-access Science Funders Announce Price Transparency Rules for Publishers (several resources on the subject) AND A new mandate highlights costs, benefits of making all scientific articles free to read – Science
Comprehensive Review | Pneumonia
9 Apr, 2021 | 03:14h | UTCPneumonia – Nature Reviews Disease Primers (free for a limited period)
Try this link if the above is paywalled.
[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil
9 Apr, 2021 | 03:36h | UTC
Commentary on Twitter (thread – click for more)
New 50% efficacy study of Brazil-predominant vaccine CoronaVac (by Sinovac) in Manaus ?? among healthcare workers when #P1 ~75% dominant. Not a trial, but the study found a 1st dose >=14-days efficacy of 50% on symptomatic #COVID19, ~32% if +asymptomatic. https://t.co/YMmZ3mmSDI pic.twitter.com/jwx5R627ys
— Eric Feigl-Ding (@DrEricDing) April 8, 2021
Commentary | Distinguishing the real from the hyperglycemia: does COVID-19 induce diabetes?
9 Apr, 2021 | 03:28h | UTC
The NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19
9 Apr, 2021 | 03:35h | UTC
Editorial by Dr. Antony Fauci: The story behind COVID-19 vaccines
9 Apr, 2021 | 03:32h | UTCThe story behind COVID-19 vaccines – Science
Audio Interview: Antibody Responses to Natural Infection and Vaccination
9 Apr, 2021 | 03:30h | UTC
COVAX reaches over 100 economies, 42 days after first international delivery
9 Apr, 2021 | 03:27h | UTC
Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation
9 Apr, 2021 | 03:09h | UTCCancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation – JCO Global Oncology